US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Prometheus Biosciences

News headline image
Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
From Prometheus Biosciences
Via GlobeNewswire
Tickers RXDX
News headline image
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
From Prometheus Biosciences
Via GlobeNewswire
Tickers MRK RXDX
News headline image
Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Prometheus Biosciences
Via GlobeNewswire
Tickers RXDX
News headline image
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
From Prometheus Biosciences
Via GlobeNewswire
Tickers RXDX
News headline image
Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO)
From Prometheus Biosciences
Via GlobeNewswire
Tickers RXDX
News headline image
Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference
From Prometheus Biosciences
Via GlobeNewswire
Tickers RXDX
News headline image
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Prometheus Biosciences
Via GlobeNewswire
Tickers RXDX
News headline image
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock
From Prometheus Biosciences
Via GlobeNewswire
Tickers RXDX
News headline image
Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
From Prometheus Biosciences
Via GlobeNewswire
Tickers RXDX
News headline image
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
From Prometheus Biosciences
Via GlobeNewswire
Tickers RXDX
News headline image
Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
From Prometheus Biosciences
Via GlobeNewswire
Tickers RXDX
News headline image
Prometheus Biosciences to Participate at November Healthcare Conferences
From Prometheus Biosciences
Via GlobeNewswire
Tickers RXDX
News headline image
Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052
From Prometheus Biosciences
Via GlobeNewswire
Tickers RXDX